Price movement over the last 24 hours
Automatic Data Processing Inc vs 10X Genomics Inc — how do they compare? Automatic Data Processing Inc trades at $241.94 (market cap $98.17B), while 10X Genomics Inc trades at $36.77 (market cap $4.80B). The key difference: Automatic Data Processing Inc is far larger — about 20.5× 10X Genomics Inc's market cap, and Automatic Data Processing Inc pays a 2.77% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| ADP | TXG | |
|---|---|---|
Market Cap | $98.17B | $4.80B |
Sector | Industrials | Health |
52-Week High | $310.94 | $40.00 |
52-Week Low | $188.79 | $11.34 |
Enterprise Value | $99.24B | $4.35B |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
ADP trades at $245.60, up 1.37% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Revenue grew to $20.56 billion in 2025, with a net income margin of 20.12%. Analyst sentiment is mixed, with a consensus hold rating but a technical outlook suggesting strength. The company maintains strong profitability metrics and recently announced a dividend payment.
Outlook remains stable with projected revenue growth to $21.6 billion in 2026. Risks include competitive pressures and economic sensitivity. Opportunities lie in AI integration and margin expansion. The stock offers value through dividends and steady performance, though valuation multiples are elevated relative to historical averages.
TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.
The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.
Trailing returns across standard periods
Latest headlines on both assets
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →